 - Phase I Administration of denileukin diftitox and vaccinations 1 to 4: Patients undergo leukapheresis for collection of peripheral blood mononuclear cells PMBC. PBMC are processed for the generation of dendritic cells DC to be used for vaccinations. DC are pulsed with HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens. DC are pulsed with or without ex vivo treatment with CD40-ligand. Patients receive denileukin diftitox IV for 3 consecutive days before the first vaccination. Patients receive 4 pulsed DC vaccinations subcutaneously SC on days 1, 14, 42, and 70 in the absence of disease progression or unacceptable toxicity. 